Cortexyme is a clinical-stage pharmaceutical company based in South San Francisco developing therapeutics to alter the course of Alzheimer’s and other degenerative diseases. Its lead small molecule, COR388, is a first-in-class, orally administered bacterial protease inhibitor that targets a pathogen Cortexyme discovered in the brains of Alzheimer’s patients. COR388 completed placebo-controlled single ascending dose and multiple ascending dose trials in healthy volunteers and was reported to be safe, well tolerated, and to show a favorable pharmacokinetic profile and tissue distribution. The company plans to start a phase 2 proof-of-efficacy study in Alzheimer’s patients next year. Additional proprietary small molecules are advancing in preclinical development. Financially, Cortexyme completed a $76 million Series B financing with participation from both new and existing investors. Cortexyme is developing therapeutics and diagnostics intended to alter the course of Alzheimer’s disease and other degenerative disorders. The company is targeting a specific, undisclosed pathogen tied to neurodegeneration and is testing several patent-pending lead therapeutics in preclinical studies. It intends to use new funding to advance ongoing development of these novel therapeutics and diagnostics. The company is led by CEO Casey Lynch and is based in South San Francisco, California. Prior to this round, Cortexyme had raised $1.025M, including an investment award from Breakout Labs. Cortexyme is a San Francisco-based healthcare technology company developing novel therapeutics and diagnostics for Alzheimer’s disease and other neurodegenerative disorders. The company is led by CEO Casey Lynch and is advancing preclinical-stage programs. Cortexyme raised $1M in funding. The round was led by evergreen fund Dolby Family Ventures, which invested $500K. The company intends to use the funds to continue preclinical research and advance its therapeutic and diagnostic programs. Cortexyme is developing therapeutics intended to alter the course of Alzheimer’s disease and other disorders of aging. Its scientific breakthrough is based on a link between a specific pathogen and human brain degeneration discovered by founder Stephen Dominy, M.D. The company plans to develop a diagnostic and treatment-monitoring method for the general population, test several patent-pending therapeutics, and develop novel small-molecule candidates. Breakout Labs announced funding to allow Cortexyme to pursue those development activities. Breakout Labs is Peter Thiel’s nonprofit fund that provides up to $350,000 to companies to achieve specific milestones. Cortexyme is based in San Francisco and is led by CEO Casey Lynch.

Total raised

$92M

Funding rounds

4

Latest round

Series B

Latest activity

May 2018